Introduction: Interestingly, the gamma and beta lineages share three common mutations (K417N/T, E484K, and N501Y) in spike protein.
Introduction: The K417N/T, E484K, and N501Y mutations significantly decreased the neutralizing activity of convalescent and messenger RNA vaccine-induced serum.
Introduction: The gamma variant was first detected in Manaus, Brazil in November, 2020 with the following lineage-defining mutations: E484K, K417T, and N501Y.
Introduction: Among them, the variants P.1 and P.2, first isolated in Brazil possess substitutions of interest in the S protein, including K417T, E484K, N501Y, D614G, and H655Y.
A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants.
PMID: 34732694
2021
Signal transduction and targeted therapy
Result: We investigated several RBD variants within publicly available SARS-CoV-2 sequences in the Global Initiative on Sharing All Influenza Data (GISAID) and all of the individual RBD mutants (N501Y, E484K, E484Q, K417N, K417T, L452R, L452Q, T478K) found in dominant VOCs (B.1.1.7, Alpha; B.1.352, Beta; P.1, Gamma; B.1.617.2, Delta; B.1.427/B.1.429, Epsilon) for n3113.1 binding.
Method: They are: Result: The B.1.351 control showed mutation in E484K, D614G, A701V, K417N, N501Y, and L242_244L, B.1.1.7 showed mutations in D614G, delH69V70, N501Y, and Q27stop, the control B.1.617.1 showed mutation in E484Q, P681R, L452R, D614G, and P.1 showed mutations in E484K, D614G, K417T, N501Y, and T20N.
Table: K417T
Epidemiology of COVID-19: An updated review.
PMID: 34759999
2021
Journal of research in medical sciences
Table: K417T
Development of an efficient Sanger sequencing-based assay for detecting SARS-CoV-2 spike mutations.
Abstract: Here, we developed five SARS-CoV-2 spike gene primer pairs (5-SSG primer assay; 69S, 144S, 417S, 484S, and 570S) and verified their ability to detect nine key spike mutations (DeltaH69/V70, T95I, G142D, DeltaY144, K417T/N, L452R, E484K/Q, N501Y, and H655Y) using a Sanger sequencing-based assay.
Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants.
Introduction: The Gamma P.1 variant encodes an S protein with 12 mutations (L18F, T20N, P26S, D138Y, R190S, K417N/T, E484K, N501Y, D614G, H655Y, T1027I, and V1176F), two of which are in the RBD (E484K, and N501Y).
Discussion: For the Alpha (B.1.1.7) and Beta (B.1.351) variants, the del 69-70, del 144, and del 242-244 deletions in NTD and the K417N/T, E484K
Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding.
Introduction: The one RBD mutation occurring outside of the RBM, K417N/T, additionally exhibits ambiguity in mutation, with the P.1 strain mutated to threonine (K417T) and the B.1.351 strain mutated to asparagine (K417N) (Figure 1B).
Discussion: Although there are many factors governing viral evolution, these results suggest that the independent evolution of L452R-bearing spikes and N501Y-, K417N/T-, and E484K-bearing spikes may be explained by a lack of synergistic increase in ACE2 binding upon combination of these mutations.
Discussion: Consistent with this hypothesis, analysis of deposited sp
The Development of SARS-CoV-2 Variants: The Gene Makes the Disease.
PMID: 34940505
2021
Journal of developmental biology
Abstract: Some concerning mutations associated with an impact on viral fitness have been described in the Spike protein, such as D614G, N501Y, E484K, K417N/T, L452R, and P681R, among others.
Introduction: Close to them within the RBD, K417N, and K417T mutations have been repeatedly described to protect against binding to certain monoclonal antibodies.
Introduction: In fact, it has been proposed that K417N could provide a slightly improved ACE2 binding compared to K417T.
Introduction: Nevertheless, both K417N and
Additional Positive Electric Residues in the Crucial Spike Glycoprotein S Regions of the New SARS-CoV-2 Variants.
SARS_CoV_2 mutation literature information.
PMID: 
2021
Journal of medical virology
Browser Board
Co-occurred Entities
Filtrator
ViMRT